Targeting tumor metabolism may improve the outcomes for patients with glioblastoma (GBM). To further preclinical efforts targeting metabolism in GBM, we tested the hypothesis that brain tumors can be stratified into distinct metabolic groups with different patient outcomes. Therefore, to determine if tumor metabolites relate to patient survival, we profiled the metabolomes of human gliomas and correlated metabolic information with clinical data.
Results:
We found that isocitrate dehydrogenase-wildtype (IDHwt) GBMs are metabolically distinguishable from IDH mutated (IDHmut) astrocytomas and oligodendrogliomas. Survival of patients with IDHmut gliomas was expectedly more favorable than those with IDHwt GBM, and metabolic signatures can stratify IDHwt GBMs subtypes with varying prognoses. Patients whose GBMs were enriched in amino acids had improved survival, while those whose tumors were enriched for nucleotides, redox molecules, and lipid metabolites fared more poorly. These findings were recapitulated in validation cohorts using both metabolomic and transcriptomic data.
Innovation:
Our results suggest the existence of metabolic subtypes of GBM with differing prognoses, and further support the concept that metabolism may drive the aggressiveness of human gliomas.
Conclusions:
Our data show that metabolic signatures of human gliomas can inform patient survival. These findings may be used clinically to tailor novel metabolically targeted agents for GBM patients with different metabolic phenotypes. Antioxid. Redox Signal. 39, 942–956.
Get full access to this article
View all access options for this article.
References
1.
AllenBG, BodekerKL, SmithMC, et al.First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma. Clin Cancer Res, 2019; 25(22):6590–6597; doi: 10.1158/1078-0432.Ccr-19-0594
BratDJ, AldapeK, ColmanH, et al.cIMPACT-NOW update 5: Recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol, 2020; 139(3):603–608; doi: 10.1007/s00401-020-02127-9
4.
CeccarelliM, BarthelFP, MaltaTM, et al.Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell, 2016; 164(3):550–563; doi: 10.1016/j.cell.2015.12.028
5.
ChinnaiyanP, KensickiE, BloomG, et al.The metabolomic signature of malignant glioma reflects accelerated anabolic metabolism. Cancer Res, 2012; 72(22):5878–5888; doi: 10.1158/0008-5472.can-12-1572-t
6.
DangL, WhiteDW, GrossS, et al.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature, 2009; 462(7274):739–744; doi: 10.1038/nature08617
7.
De RosaA, PellegattaS, RossiM, et al.A radial glia gene marker, fatty acid binding protein 7 (FABP7), is involved in proliferation and invasion of glioblastoma cells. PLoS One, 2012; 7(12):e52113; doi: 10.1371/journal.pone.0052113
8.
Eckel-PassowJE, LachanceDH, MolinaroAM, et al.Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med, 2015; 372(26):2499–2508; doi: 10.1056/NEJMoa1407279
9.
FaubertB, TasdoganA, MorrisonSJ, et al.Stable isotope tracing to assess tumor metabolism in vivo. Nat Protoc, 2021; 16(11):5123–5145; doi: 10.1038/s41596-021-00605-2
10.
GaoX, SandersonSM, DaiZ, et al.Dietary methionine influences therapy in mouse cancer models and alters human metabolism. Nature, 2019; 572(7769):397–401; doi: 10.1038/s41586-019-1437-3
GoldmanMJ, CraftB, HastieM, et al.Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol, 2020; 38(6):675–678; doi: 10.1038/s41587-020-0546-8
13.
HanafordAR, AltJ, RaisR, et al.Orally bioavailable glutamine antagonist prodrug JHU-083 penetrates mouse brain and suppresses the growth of MYC-driven medulloblastoma. Transl Oncol, 2019; 12(10):1314–1322; doi: 10.1016/j.tranon.2019.05.013
14.
HanahanD. Hallmarks of cancer: New dimensions. Cancer Discov, 2022; 12(1):31–46; doi: 10.1158/2159-8290.cd-21-1059
15.
HartmannC, MeyerJ, BalssJ, et al.Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathol, 2009; 118(4):469–474; doi: 10.1007/s00401-009-0561-9
16.
KachmanM, HabraH, DurenW, et al.Deep annotation of untargeted LC-MS metabolomics data with Binner. Bioinformatics, 2019; 36(6):1801–1806; doi: 10.1093/bioinformatics/btz798
17.
KantS, KesarwaniP, PrabhuA, et al.Enhanced fatty acid oxidation provides glioblastoma cells metabolic plasticity to accommodate to its dynamic nutrient microenvironment. Cell Death Dis, 2020; 11(4):253; doi: 10.1038/s41419-020-2449-5
18.
Karpel-MasslerG, RamaniD, ShuC, et al.Metabolic reprogramming of glioblastoma cells by L-asparaginase sensitizes for apoptosis in vitro and in vivo. Oncotarget, 2016; 7(23):33512–33528; doi: 10.18632/oncotarget.9257
19.
KesarwaniP, PrabhuA, KantS, et al.Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma. Cancer Immunol Immunother, 2019; 68(7):1107–1120; doi: 10.1007/s00262-019-02347-3
20.
KofujiS, HirayamaA, EberhardtAO, et al.IMP dehydrogenase-2 drives aberrant nucleolar activity and promotes tumorigenesis in glioblastoma. Nat Cell Biol, 2019; 21(8):1003–1014; doi: 10.1038/s41556-019-0363-9
21.
KuhnM, Von MeringC, CampillosM, et al.STITCH: Interaction networks of chemicals and proteins. Nucleic Acids Res, 36(Database issue)2008;:D684–D688; doi: 10.1093/nar/gkm795
22.
LaiA, KharbandaS, PopeWB, et al.Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol, 2011; 29(34):4482–4490; doi: 10.1200/JCO.2010.33.8715
23.
LeeHJ, KremerDM, SajjakulnukitP, et al.A large-scale analysis of targeted metabolomics data from heterogeneous biological samples provides insights into metabolite dynamics. Metabolomics, 2019; 15(7):103; doi: 10.1007/s11306-019-1564-8
24.
LinH, PatelS, AffleckVS, et al.Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells. Neuro Oncol, 2017; 19(1):43–54; doi: 10.1093/neuonc/now128
25.
LiuJ, LichtenbergT, HoadleyKA, et al.An Integrated TCGA Pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell, 2018; 173(2):400–416; doi: 10.1016/j.cell.2018.02.052
26.
LouisDN, PerryA, ReifenbergerG, et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol, 2016; 131(6):803–820; doi: 10.1007/s00401-016-1545-1
27.
LouisDN, PerryA, WesselingP, et al.The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro Oncol, 2021; 23(8):1231–1251; doi: 10.1093/neuonc/noab106
28.
MajdN, SumitaK, YoshinoH, et al.A review of the potential utility of mycophenolate mofetil as a cancer therapeutic. J Cancer Res, 2014; 2014:1–12; doi: 10.1155/2014/423401
29.
MercatelliD, Lopez-GarciaG, GiorgiFM. Corto: A lightweight R package for gene network inference and master regulator analysis. Bioinformatics, 2020; 36(12):3916–3917; doi: 10.1093/bioinformatics/btaa223
30.
PangZ, ChongJ, ZhouG, et al.MetaboAnalyst 5.0: Narrowing the gap between raw spectra and functional insights. Nucleic Acids Res, 2021; 49(W1):W388–W396; doi: 10.1093/nar/gkab382
31.
ParsonsDW, JonesS, ZhangX, et al.An integrated genomic analysis of human glioblastoma multiforme. Science, 2008; 321(5897):1807–1812; doi: 10.1126/science.1164382
32.
PattiGJ, YanesO, SiuzdakG. Innovation: Metabolomics: The apogee of the omics trilogy. Nat Rev Mol Cell Biol, 2012; 13(4):263–269; doi: 10.1038/nrm3314
33.
PrabhuAH, KantS, KesarwaniP, et al.Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma. Neuro Oncol, 2019; 21(3):337–347; doi: 10.1093/neuonc/noy185
34.
SchoenfeldJD, SibenallerZA, MapuskarKA, et al.O2(-) and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM cancer cells to pharmacological ascorbate. Cancer Cell, 2017; 32(2):268; doi: 10.1016/j.ccell.2017.07.008
35.
SchwarzJK, SiegelBA, DehdashtiF, et al.Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA, 2007; 298(19):2289–2295; doi: 10.1001/jama.298.19.2289
36.
ScottAJ, LyssiotisCA, WahlDR. Clinical targeting of altered metabolism in high-grade glioma. Cancer J, 2021; 27(5):386–394; doi: 10.1097/ppo.0000000000000550
37.
ShenoudaG, SouhamiL, PetreccaK, et al.A Phase 2 Study of Neo-adjuvant Metformin and Temozolomide followed by Hypofractionated Accelerated RadioTherapy (HART) with Concomitant and Adjuvant Metformin and Temozolomide (TMZ) in Patients with Glioblastoma. Int J Radiat Oncol Biol Phys, 2020; 108(3):S21; doi: 10.1016/j.ijrobp.2020.07.2107
38.
ShiDD, SavaniMR, LevittMM, et al.De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma. Cancer Cell, 2022; 40(9):939–956; doi: 10.1016/j.ccell.2022.07.011
39.
ShiremanJM, AtashiF, LeeG, et al.De novo purine biosynthesis is a major driver of chemoresistance in glioblastoma. Brain, 2021; 144(4):1230–1246; doi: 10.1093/brain/awab020
40.
SuchorskaB, JansenNL, LinnJ, et al.Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM. Neurology, 2015; 84(7):710–719; doi: 10.1212/wnl.0000000000001262
41.
TesileanuCMS, SansonM, WickW, et al.Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clin Cancer Res, 2022; 28(12):2527–2535; doi: 10.1158/1078-0432.Ccr-21-4283
42.
VerhaakRGW, HoadleyKA, PurdomE, et al.Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010; 17(1):98–110; doi: 10.1016/j.ccr.2009.12.020
WangX, YangK, XieQ, et al.Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. Nat Neurosci, 2017; 20(5):661–673; doi: 10.1038/nn.4537
45.
ZhouW, YaoY, ScottAJ, et al.Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nat Commun, 2020; 11(1):3811; doi: 10.1038/s41467-020-17512-x
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
